Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Use of pioglitazone in people with type 2 diabetes mellitus with coronavirus disease 2019 (COVID-19): Boon or bane?

Mukherjee Jagat J, Gangopadhyay Kalyan K, Ray Subir a

a Apollo Gleneagles Hospitals, 58, Canal Circular Road, Kolkata, 700054, India
b Fortis Hospital, 730, Eastern Metropolitan Bypass, Kolkata, 700107, India

ARTICLE INFO

Article history:
Received 26 May 2020
Received in revised form 5 June 2020
Accepted 8 June 2020

Keywords:
Coronavirus disease 2019 (COVID-19)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Pioglitazone
PPAR-ɤ agonist
Angiotension converting enzyme 2
Inflammation
Cytokine storm

ABSTRACT

Background and aims: People with type 2 diabetes mellitus (T2DM) have increased morbidity and mortality due to coronavirus disease 2019 (COVID-19). It has been speculated that use of pioglitazone might increase such risk. The aim of our brief commentary is to review the safety of pioglitazone in people with T2DM and mild/moderate COVID-19.

Methods: We searched PubMed database using specific keywords related to our aims till May 15, 2020. Full text of relevant articles published in English language were retrieved and reviewed.

Results: Medications, including pioglitazone, that upregulate tissue expression of angiotensin converting enzyme 2 (ACE2), might have a dual role in COVID-19; on the one hand they might increase risk of infection as SARS-CoV2 uses ACE2 as a coreceptor to enter alveolar cells, but on the other hand, by reducing angiotensin II levels, they can protect against acute lung injury. There is no evidence to date that pioglitazone upregulates ACE2 in the alveolar cells; rather, there is evidence from animal studies of downregulation of ACE2 might have a dual action in people with diabetes with COVID-19: on the one hand and reducing the severity of lung injury on the other. Moreover by moderating the exaggerated host proinflammatory response, pioglitazone can potentially reduce SARS-CoV-2 driven hyperinflammation.

Conclusions: Pioglitazone has more potential for benefit than harm, and can be continued in people with T2DM and mild/moderate COVID-19, unless there are specific contraindications for its use. There is an urgent need to assess clinically relevant outcomes in people with diabetes and COVID-19 based upon baseline antidiabetes therapy, in particular pioglitazone.

© 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.
prescription for people with diabetes in many Asian countries; in a study reported in 2016 from India, depending upon the region sampled, 7.9–13.4% of all antidiabetic drug prescriptions in outpatient departments was pioglitazone [6]. The ADA–EASD 2018 guidelines also recommend using pioglitazone in situations where cost is a factor in decision making. (see Table 1)

Pioglitazone belongs to the thiazolidinedione (TZD) group of medications, and acts as an agonist of the peroxisome proliferator–activated receptor (PPAR)-γ. Recent publications have alluded to upregulation of ACE2 by pioglitazone [7]. Indeed, animal studies have shown that pioglitazone increases the expression of ACE2 in the liver, adipose tissue and skeletal muscles [2]. However, pioglitazone was found to have no effect on cardiac ACE2 expression in a study on db/db mice [8]. As such, apart from upregulation of ACE2 in insulin sensitive tissues in animals, unlike ACEi/ARB, there is no evidence that pioglitazone upregulates expression of ACE2 in alveolar cells. On the other hand, Wu et al. have interestingly postulated a possible therapeutic role for pioglitazone in SARS-CoV-2 infection [9]. In their quest for finding a treatment for COVID-19, they embarked on bioinformatic analysis of marketed molecules, using virtual ligand screening method, on various proteins encoded by SARS-CoV-2. The 3-chymotrypsin-like protease (3CLPro) is one such non-structural protein that is essential for SARS-CoV-2 RNA synthesis and replication. Pioglitazone was found to have potential to act as 3CL-Pro inhibitor, which could inhibit SARS-CoV-2 RNA synthesis and replication; however, this nascent concept needs substantiation with further research.

Pioglitazone may also play an important role in people with diabetes with COVID-19 by moderating host inflammatory response at multiple fronts. Subsets of people with diabetes and COVID-19 have SARS-CoV-2 driven hyperinflammation and severe cytokine storm syndrome. A number of immunosuppressive agents, including anakinra [interleukin (IL)-1 blocker] and tocilizumab (IL-6 blocker) are being studied to counter this SARS-CoV-2 driven hyper inflammation [10]. PPAR-γ agonists have also been shown to decrease the secretion of various pro-inflammatory cytokines, including tumour-necrosis factor-α (TNF-α), IL-1, and IL-6 in the monocytes and macrophages [11]. PPAR-γ agonists in particular has been shown to reduce the expression of caspase-recruitment domain-containing protein 9 (CARD9), which in turn inhibits the activation of nuclear factor kappa-light-chain-enhancer of activated B cells and mitogen-activated protein kinase pathways in macrophages [12]. Adipose tissue is also an active contributor to inflammation, and releases a variety of proinflammatory proteins including TNF-α, IL-6 and monocyte chemoattractant protein-1 (MCP-1). Animal studies have revealed that pioglitazone can suppress TNF-α and IL-6 generation in adipose tissue [13]. Pioglitazone has been shown in animal studies to decrease mortality from sepsis and lung injury by reducing inflammatory cytokine production in omental tissue [13]. Interestingly, this moderation in cytokine production at multiple fronts by pioglitazone has led researchers to speculate on its role in the treatment of COVID-19 associated cytokine storm. However, lack of parallelism between humans and mice may blunt the translational value of these findings.

In summary, in a rapidly evolving pandemic situation of COVID-19, it is essential to generate evidence quickly to guide management. Pioglitazone is an inexpensive anti-diabetic agent that is used commonly around the globe. It is hence essential to review its safety in people with diabetes with COVID-19. In balance, as argued above, we feel pioglitazone has more potential for benefit than harm, and can be safely continued in people with diabetes and COVID-19 unless there are specific contraindications for use of pioglitazone. More evidence from the laboratory and the clinics are urgently needed to guide the clinician. Among these, retrospective analyses of outcomes in people with diabetes with COVID-19 who were on pioglitazone can serve as a good evidence base. However, most retrospective observational case studies published to date do not have this information. As such, there is an urgent need to assess clinically relevant outcomes, including risk for developing severe disease, risk for hospitalisation and risk of death, among people with diabetes with COVID-19 based on baseline anti-diabetic therapy, in particular pioglitazone.

**Funding**

None.

**Declaration of competing interest**

No conflict of interest to declare.

**References**

[1] Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020. https://doi.org/10.1007/s00134-020-05985-9.

[2] Zhang W, Xu YZ, Liu Bo, Wu R, Yang Y, Xiao X, et al. Pioglitazone upregulated angiotensin converting enzyme 2 expression in insulin-sensitive tissues in rats with high-fat diet-induced non-alcoholic steatohepatitis. Sci World J 2014;603409. https://doi.org/10.1155/2014/603409.

[3] Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibitor and angiotensin II receptor inhibitor...
blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005;111:2605–10.
[4] Liu Y, Yang Y, Zhang C, Fengming H, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 2020;63:364–74.
[5] Kassiri Z, Zhong J, Guo D, Basu R, Wang X, Liu PP, et al. Loss of angiotensin-converting enzyme 2 accelerated maladaptive left ventricular remodelling in response to myocardial infarction. Circ Heart Fail 2009;2:446–55.
[6] Pai SA, Kshirsagar NA. Pioglitazone utilization, efficacy & safety in Indian type 2 diabetic patients: a systematic review & comparison with European Medicines Agency Assessment Report. Indian J Med Res 2016;144(5):672–81.
[7] Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020;8(4). https://doi.org/10.1016/S2213-2600(20)30116-8. e21.
[8] Fadnavis R. Effect of hyperglycemia and thiazolidinediones on cardiac angiotensin converting enzyme 2 (ACE2) and neprilysin (NEP) in db/db diabetic mice. Browse all Theses and Dissertations. 2080. 2017. https://corescholar.libraries.wright.edu/etd_all/2080.
[9] Canrong Wu, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B https://doi.org/10.1016/j.apsb.2020.02.008.
[10] Fandino J, Vaz AA, Toba L, Romani-Pérez M, González-Matías I, Mallo F, et al. Liraglutide enhances the activity of the ACE2/Ang(1-7) Mas receptor pathway in lungs of male pups from food-restricted mothers and prevents the reduction of SP-A. Internet J Endocrinol 2018. https://doi.org/10.1155/2018/6920620. Volume 2018 [Article ID 6920620 ].
[11] Bassaganya-Riera J, Song R, Roberts PC, Hontecillas R. PPAR-gamma activation as an anti-inflammatory therapy for respiratory virus infections. Viral Immunol 2010;23:343–52.
[12] Kock G, Bringmann A, Held SAE, Heine A, Brossart P. Regulation of dectin-1 mediated dendritic cell activation by peroxisome proliferator-activated receptor-gamma ligand troglitazone. Blood. 2011 Mar 31;117(13):3569–74. https://doi.org/10.1182/blood-2010-08-302224.
[13] Kutsukake M, Matsutani T, Tamura K, Matsuda A, Kpobayasi M, Tachikawa E, et al. Pioglitazone attenuates lung injury by modulating adipose inflammation. J Surg Res 2014;189:295–303.